Gianluca Interlandi

This study designs miniprotein inhibitors targeting bacterial adhesins to prevent and treat urinary tract infections.

This study investigates FimH conformational dynamics and catch bond formation using a single-domain variant, revealing ultra-slow dynamics and a dynamic allosteric mechanism.

This study identifies four antibody mechanisms that disrupt FimH-mediated bacterial adhesion by altering its conformation and glycan binding.

This study develops an assay to test drugs that inhibit von Willebrand factor selectively under oxidizing inflammatory conditions, finding lumacaftor may do so effectively.

This paper identifies a ligand that selectively binds to the A1A2 interface of von Willebrand factor under oxidizing conditions, potentially restoring auto-inhibition during inflammation.